Myovant Sciences Initiates Phase 3 Clinical Program of Relugolix in Women with Heavy Menstrual Bleeding Associated with Uterine Fibroids
January 25, 2017 at 07:00 am
Myovant Sciences announced it has initiated a Phase 3 clinical program consisting of two international clinical trials, LIBERTY 1 and LIBERTY 2, to evaluate the safety and efficacy of relugolix in women with heavy menstrual bleeding associated with uterine fibroids. Relugolix is an oral, once-daily, small molecule gonadotropin-releasing hormone (GnRH) receptor antagonist that decreases estrogen and progesterone. It will be evaluated with and without low-dose hormonal add-back therapy.